Paychex stock (NASDAQ: PAYX) is down 3% since the beginning of this year, but at the current price of around $83 per share, we believe that PAYX stock has around 15% potential downside.
Why is that? Our belief stems from the fact that PAYX stock is still up almost 60% from the low seen in March, compared to the S&P which is up around 55%. Further, after posting weak Q1 2021 numbers, and with demand still not up to pre-Covid levels, we believe Paychex’s stock could drift lower. Our dashboard What Factors Drove 3% Change In Paychex Stock Between 2019 And Now? provides the key numbers behind our thinking, and we explain more below.
PAYX stock’s rise since late 2019 came due to a 7% rise in revenues, which translated into a 6% rise in net income. A roughly unchanged share count meant that earnings per share (EPS) also rose 6%.
Paychex’s P/E (price-to-earnings) ratio dropped from 30x in 2019 to 27x in 2020, due to lower investor expectations as the pandemic especially affected a lot of small and mid-size businesses, Paychex’s primary client pool. Further, given Paychex’s poor Q1 ’21 numbers and the fact that demand is still not back to pre-Covid levels, there is further possible downside risk for Paychex’s multiple, especially when compared with previous years: P/E of 24x at the end of 2016 and 23x as recently as late-2018.
So what’s the likely trigger and timing to this downside?
The global spread of Coronavirus, and the resulting lock downs and quarantine means that a lot of businesses are struggling, and may want to cut costs. Most of Paychex’s clients are small and mid-size businesses, and it is likely that they would want to shift HR and payroll processing activities in-house, instead of outsourcing. This is evident from Paychex’s Q1 ’21 results where revenue dropped to $932 million from $992 million for the same period last year. A rise in SG&A expenses meant that EPS took a bigger hit, dropping from $0.74 to $0.59 over the same period.
We expect Paychex’s business to struggle to get back to pre-Covid levels in the medium term and if there isn’t clear evidence of containment of the virus anytime soon, we believe the stock will see its P/E multiple decline from the current level of 27x to around 24x, which combined with a slight reduction in revenues and margins could result in the stock price shrinking to as low as $70, a downside of around 15% from the current price of $83.
What if you’re looking for a more balanced portfolio instead? Here’s a high quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.